Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY4R | P50391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21784542 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5CA1 | |
| SCHEMBL24822727 | 0.89 | SIRT2 (0.44) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL18823483 | 0.89 | SIRT2 (0.43) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL18822244 | 0.88 | SIRT2 (0.40) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL24451192 | 0.87 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL24471964 | 0.87 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL25098213 | 0.87 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL21318749 | 0.87 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL20283603 | 0.87 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL19485764 | 0.87 | FURIN (0.44) | SIRT2SIRT1SIRT3SIRT5HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666657-B2 | Protein-drug conjugates and their use in the treatment of cancers | UNIVERSITE DE STRASBOURG (FR) | 2023-06-06 | — | — | US | disclosed |
| US-20200069815-A1 | PROTEIN-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666657-B2 | Protein-drug conjugates and their use in the treatment of cancers | RCE1, MTTP, LYPLA1 | SIRT2 2551/4885SIRT1 2552/4885SIRT3 2269/4885 |
| US-20200069815-A1 | PROTEIN-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCERS | RCE1, MTTP, LYPLA1 | SIRT2 2551/4885SIRT1 2552/4885SIRT3 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.